Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ketamine add-on trial for major depressive disorder
ACTRN12615000566538Phase 3Recruiting
- Sponsor
- National University of Singapore
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ketamine in major depressive disorder (MDD) (3 arms), sponsored by National University of Singapore. Primary endpoint: Change in depression severity using Montgomery-Asberg Depression Rating Scale. Started Jun 2015; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12615000566538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000566538.